<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27662653</article-id><article-id pub-id-type="pmc">5035078</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0162787</article-id><article-id pub-id-type="publisher-id">PONE-D-15-46991</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Digestive System</subject><subj-group><subject>Salivary Glands</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Digestive System</subject><subj-group><subject>Salivary Glands</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Exocrine Glands</subject><subj-group><subject>Salivary Glands</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Exocrine Glands</subject><subj-group><subject>Salivary Glands</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Histology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Histology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Ultrasound Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Ultrasound Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Radiology and Imaging</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Ultrasound Imaging</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Biopsy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Digestive System</subject><subj-group><subject>Salivary Glands</subject><subj-group><subject>Submandibular Glands</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Digestive System</subject><subj-group><subject>Salivary Glands</subject><subj-group><subject>Submandibular Glands</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Exocrine Glands</subject><subj-group><subject>Salivary Glands</subject><subj-group><subject>Submandibular Glands</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Exocrine Glands</subject><subj-group><subject>Salivary Glands</subject><subj-group><subject>Submandibular Glands</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Fatigue</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Fatigue</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sj&#x000f6;gren&#x02019;s Syndrome: Data from the TEARS Randomized Trial</article-title><alt-title alt-title-type="running-head">SGUS and Rituximab Response in pSS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cornec</surname><given-names>Divi</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jousse-Joulin</surname><given-names>Sandrine</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marhadour</surname><given-names>Thierry</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marcorelles</surname><given-names>Pascale</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Berthelot</surname><given-names>Jean-Marie</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hachulla</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hatron</surname><given-names>Pierre-Yves</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Goeb</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vittecoq</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nowak</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pers</surname><given-names>Jacques-Olivier</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Devauchelle-Pensec</surname><given-names>Val&#x000e9;rie</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Saraux</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Service de Rhumatologie, H&#x000f4;pital de la Cavale Blanche, CHRU Brest, Boulevard Tanguy Prigent, 29609 Brest, France</addr-line></aff><aff id="aff002"><label>2</label><addr-line>EA2216, INSERM ESPRI, ERI29, Laboratoire d&#x02019;Immunoth&#x000e9;rapies et Pathologies lymphocytaires B, Universit&#x000e9; de Brest, and Labex "IGO", Brest, France</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Laboratoire d&#x02019;Anatomie Pathologique et Cytologie, H&#x000f4;pital Morvan, CHRU Brest, Avenue Foch, 29609 Brest, France</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Service de Rhumatologie, H&#x000f4;tel-Dieu, CHU Nantes, 44093 Nantes Cedex 01, France</addr-line></aff><aff id="aff005"><label>5</label><addr-line>Service de M&#x000e9;decine Interne, Claude Huriez Hospital, Universit&#x000e9; Lille Nord-de-France, 59037 Lille Cedex, France</addr-line></aff><aff id="aff006"><label>6</label><addr-line>Service de Rhumatologie, CHRU de Rouen, 76230 Bois-Guillaume, France</addr-line></aff><aff id="aff007"><label>7</label><addr-line>INSERM CIC 0502, CHU Brest, Brest, France</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Chopra</surname><given-names>Arvind</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Center for Rheumatic Diseases, INDIA</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>EH, VG, VDP, and AS have received consulting fees from Roche, less than 10 000 US$ each. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceived and designed the experiments:</bold> DC SJJ SC JOP VDP AS.</p></list-item><list-item><p><bold>Performed the experiments:</bold> DC SJJ SC TM PM JMB EH PYH VG OV EN JOP VDP AS.</p></list-item><list-item><p><bold>Analyzed the data:</bold> DC EN AS.</p></list-item><list-item><p><bold>Wrote the paper:</bold> DC AS.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>alain.saraux@chu-brest.fr</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>9</issue><elocation-id>e0162787</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Cornec et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Cornec et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0162787.pdf"/><abstract><sec id="sec001"><title>Purpose</title><p>To determine whether the severity of salivary-gland involvement, assessed using salivary gland ultrasonography [SGUS], histological focus score, or the unstimulated whole salivary flow [UWSF], was associated with the response to rituximab in patients with primary Sj&#x000f6;gren&#x02019;s syndrome [pSS].</p></sec><sec id="sec002"><title>Materials and Methods</title><p>Among the 120 patients with pSS enrolled in the randomised TEARS trial of rituximab versus placebo, 35 underwent either centralised minor salivary-gland biopsy or SGUS at inclusion. The echostructure of each parotid and submandibular gland was graded on a scale of 0 to 4. Histologic minor salivary gland involvement was assessed by the focus score. Among rituximab-treated patients with available data (n = 14), half met the Sj&#x000f6;gren&#x02019;s Syndrome Responder Index [SSRI]-30 definition of a response at week 24.</p></sec><sec id="sec003"><title>Results</title><p>The SGUS score correlated positively to the focus score [r = 0.61] and negatively to the UWSF [r = -0.68]. The focus score was not correlated to the UWSF. The median total SGUS grade at inclusion was 9 [6-11] in responders versus 16 [11-16] in non-responders [<italic>p</italic> = 0.04]. The proportion of SSRI-30 responders was 0% among patients with SGUS grade 4 and 88% among those with SGUS grade &#x02264;3. Low baseline SGUS scores were associated with sicca-related outcomes improvement, but not with fatigue or biological improvement. Median baseline focus score was 0.3 [0.0&#x02013;1.3] in the responders versus 4.0 [2.7&#x02013;5.3] in the non-responders [<italic>p</italic> = 0.02]. Baseline UWSF was not associated with the response rate.</p></sec><sec id="sec004"><title>Conclusion</title><p>In patients with pSS, the highest SGUS grade or a high histological focus score is associated with absence of a response to a single rituximab course after 6 months. Further studies, including more patients and different treatment strategies, are required to confirm the clinical utility of these potential biomarkers in pSS.</p></sec></abstract><funding-group><funding-statement>The TEARS study was funded by the French public funding agency Programme Hospitalier de Recherche Clinique (PHRC) 2010. Rituximab was donated by Roche.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="11"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Primary Sj&#x000f6;gren&#x02019;s syndrome [pSS] is a systemic autoimmune disease clinically characterised by intense fatigue and by oral and ocular dryness, reflecting lymphocytic infiltration and subsequent dysfunction of the exocrine glands. Its prevalence is estimated at about 40/100 000 inhabitants in Europe [<xref rid="pone.0162787.ref001" ref-type="bibr">1</xref>].</p><p>No treatments have been proven to modify the natural course of the disease. The few large randomised controlled studies in patients with pSS showed no significant efficacy of TNF-alpha antagonists [<xref rid="pone.0162787.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0162787.ref003" ref-type="bibr">3</xref>] or hydroxychloroquine [<xref rid="pone.0162787.ref004" ref-type="bibr">4</xref>]. Recent evidence suggested benefits from rituximab therapy [<xref rid="pone.0162787.ref005" ref-type="bibr">5</xref>]. However, the larger TEARS trial [<xref rid="pone.0162787.ref006" ref-type="bibr">6</xref>] failed to detect a therapeutic effect of rituximab, indicating either lack of efficacy of this agent or low sensitivity to change of the primary endpoint. We recently developed the Sj&#x000f6;gren&#x02019;s Syndrome Response Index (SSRI)-30, a data-driven composite index of treatment response including symptoms (oral and ocular dryness and fatigue) and objective measurements (salivary flow and erythrocyte sedimentation rate) [<xref rid="pone.0162787.ref007" ref-type="bibr">7</xref>]. In the TEARS trial, about half the rituximab-treated patients achieved the SSRI-30 versus 10&#x02013;20% in the placebo arm [<xref rid="pone.0162787.ref007" ref-type="bibr">7</xref>].</p><p>A major goal of research in the field is now the identification of specific baseline characteristics/biomarkers to predict the response to therapy. The level of involvement of the target organs could be determinant in the efficacy of treatments. In a previous study [<xref rid="pone.0162787.ref008" ref-type="bibr">8</xref>], only patients with total stimulated salivary flow &#x0003e;0.1 ml/min displayed a functional salivary gland improvement after rituximab.</p><p>Salivary gland ultrasonography (SGUS) is being widely used for pSS diagnosis [<xref rid="pone.0162787.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0162787.ref017" ref-type="bibr">17</xref>]. The main pathological feature is the presence of hypoechoic area. An international expert group has been recently created in order to standardize the procedure, in the ultimate goal of including SGUS as an additional item in future classification criteria [<xref rid="pone.0162787.ref018" ref-type="bibr">18</xref>]. Besides this diagnostic value, we have previously shown that parotid ultrasonographic score (based on the number and size of hypoechoic area) improved in half of the rituximab-treated patients in the TEARS trial, compared to 7% of the patients allocated to the placebo [<xref rid="pone.0162787.ref019" ref-type="bibr">19</xref>]. SGUS score is correlated with disease activity [<xref rid="pone.0162787.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0162787.ref012" ref-type="bibr">12</xref>]. Consequently, SGUS could also be a biomarker predictive of the response to therapy.</p><p>Finally, several articles reported that the intensity of the histological inflammation, represented by the focus score, is associated to disease activity and has a prognostic value for disease severity [<xref rid="pone.0162787.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0162787.ref021" ref-type="bibr">21</xref>]. Thus, the intensity of salivary gland inflammation, assessed by the focus score, could be associated with the response to an active treatment [<xref rid="pone.0162787.ref022" ref-type="bibr">22</xref>].</p><p>Our objective here was to determine whether the severity of salivary-gland involvement as assessed morphologically [SGUS], histologically, or functionally [salivary flow], predicted the response to rituximab in patients with pSS.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Patients and Methods</title><sec id="sec007"><title>Patients</title><p>The TEARS study [<xref rid="pone.0162787.ref006" ref-type="bibr">6</xref>] was a multicentre double-blind randomised controlled trial performed in France between March 6, 2008 and January 5, 2011 to compare rituximab [two 1-g infusions two weeks apart] and a placebo in 122 patients meeting AECG criteria for pSS [<xref rid="pone.0162787.ref023" ref-type="bibr">23</xref>]. Randomization was stratified by site. A computer-generated random allocation sequence was prepared by our statistics department in Brest. All patients had either recent-onset [&#x0003c;10 years] and biologically active disease [presence of auto-antibodies or B-cell activation markers] or systemic disease. Patients were followed until week [W] 24. The detailed description of the TEARS trial protocol and results has been already published [<xref rid="pone.0162787.ref006" ref-type="bibr">6</xref>], the detailed protocol is available on PlosOne website as supporting information (<xref ref-type="supplementary-material" rid="pone.0162787.s001">S1 Checklist</xref>, <xref ref-type="supplementary-material" rid="pone.0162787.s003">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0162787.s004">S2</xref> Protocols). The TEARS trial was approved by the appropriate ethics committee [Comit&#x000e9; de Protection des Personnes (CPP) Ouest VI, #2007/493] in 2007, prior to first patient recruitment. All patients gave their signed written informed consent to participate in the TEARS study, as approved by the ethics committee. The TEARS study was registered on ClinicalTrials (ClinicalTrials.gov: NCT00740948) in August 2008 soon after the enrolment of the first patients, since this registration as not required by French authorities before the beginning of a trial at this time. The authors confirm that all ongoing and related trials for this intervention are registered.</p><p>The present study is an ancillary analysis of the TEARS study, focusing on patients who underwent in-depth salivary-gland evaluation (by histology and/or ultrasonography) at baseline (dataset available online as <xref ref-type="supplementary-material" rid="pone.0162787.s002">S1 Dataset</xref> file). Of these 122 patients, 35 [<xref ref-type="table" rid="pone.0162787.t001">Table 1</xref> and <xref ref-type="fig" rid="pone.0162787.g001">Fig 1</xref>] underwent either a minor salivary gland biopsy [MSGB] evaluated centrally at the Brest Teaching Hospital or salivary-gland ultrasonography [SGUS], and had unstimulated whole salivary flow [UWSF] measurement at baseline. Patients were instructed not to eat, drink or smoke for 90 min before UWSF measurement. All UWSF assessements were performed at the same time of the day for each patient during the clinical visit of the trial. Saliva was collected during 15 min, weighted, and UWSF was expressed as mL/min. MSGB and SGUS were performed at the discretion of the evaluating physician, as anticipated in the TEARS trial protocol, and were not required for patient&#x02019;s participation in the study. SGUS was performed only in the Brest center, which included 28 patients. Therefore, those procedures were not available for all patients participating in the TEARS trial. These 35 patients form the basis for the present study; 17 were allocated at random to rituximab and 18 to the placebo.</p><table-wrap id="pone.0162787.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0162787.t001</object-id><label>Table 1</label><caption><title>Groups of patients.</title></caption><alternatives><graphic id="pone.0162787.t001g" xlink:href="pone.0162787.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Total population N = 35<xref ref-type="table-fn" rid="t001fn001">*</xref></th><th align="left" rowspan="1" colspan="1">Rituximab responders N = 7</th><th align="left" rowspan="1" colspan="1">Rituximab non-responders N = 7</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Female, n [%]</td><td align="left" rowspan="1" colspan="1">34 [97]</td><td align="left" rowspan="1" colspan="1">6 [86]</td><td align="left" rowspan="1" colspan="1">7 [100]</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, median [IQR]</td><td align="left" rowspan="1" colspan="1">53 [45&#x02013;61]</td><td align="left" rowspan="1" colspan="1">46 [3&#x02013;55]</td><td align="left" rowspan="1" colspan="1">52 [40&#x02013;55]</td><td align="left" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">Years since diagnosis, median [IQR]</td><td align="left" rowspan="1" colspan="1">2 [1&#x02013;5]</td><td align="left" rowspan="1" colspan="1">1 [0.3&#x02013;4]</td><td align="left" rowspan="1" colspan="1">3 [1&#x02013;7]</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Abnormal Schirmer&#x02019;s test, n [%]</td><td align="left" rowspan="1" colspan="1">18 [51]</td><td align="left" rowspan="1" colspan="1">4 [57]</td><td align="left" rowspan="1" colspan="1">4 [57]</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Salivary flow &#x0003c;0.1 mL/min, n [%]</td><td align="left" rowspan="1" colspan="1">26 [74]</td><td align="left" rowspan="1" colspan="1">5 [71]</td><td align="left" rowspan="1" colspan="1">6 [86]</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Salivary flow [mL/min], median [IQR]</td><td align="left" rowspan="1" colspan="1">0.09 [0.04&#x02013;0.14]</td><td align="left" rowspan="1" colspan="1">0.1 [0.06&#x02013;0.14]</td><td align="left" rowspan="1" colspan="1">0.04 [0&#x02013;0.09]</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-SSA/SSB positivity, n [%]</td><td align="left" rowspan="1" colspan="1">31 [89]</td><td align="left" rowspan="1" colspan="1">6 [86]</td><td align="left" rowspan="1" colspan="1">7 [100]</td><td align="left" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Centralised MSGB, n</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Focus score, median [IQR]</td><td align="left" rowspan="1" colspan="1">1.3 [0.0&#x02013;5.0]</td><td align="left" rowspan="1" colspan="1">0.3 [0.0&#x02013;1.3]</td><td align="left" rowspan="1" colspan="1">4.0 [2.7&#x02013;5.3]</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">SGUS performed, n</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Highest single-gland SGUS grade, median [IQR]<xref ref-type="table-fn" rid="t001fn002">**</xref></td><td align="left" rowspan="1" colspan="1">3 [3&#x02013;4]</td><td align="left" rowspan="1" colspan="1">3 [2&#x02013;3]</td><td align="left" rowspan="1" colspan="1">4 [3&#x02013;4]</td><td align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Total SGUS grade, median [IQR]<xref ref-type="table-fn" rid="t001fn003">***</xref></td><td align="left" rowspan="1" colspan="1">9 [7&#x02013;12]</td><td align="left" rowspan="1" colspan="1">9 [6&#x02013;11]</td><td align="left" rowspan="1" colspan="1">16 [11&#x02013;16]</td><td align="left" rowspan="1" colspan="1">0.04</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>*17 patients were allocated at random to rituximab and 18 to the placebo. 3 patients had missing data precluding the computation of the Sj&#x000f6;gren&#x02019;s Syndrome Responder Index (SSRI)-30 at W24.</p></fn><fn id="t001fn002"><p>**The single-gland grade can range from 0 to 4.</p></fn><fn id="t001fn003"><p>***The total grade can range from 0 to 16.</p></fn><fn id="t001fn004"><p>IQR, interquartile range; MSGB, minor salivary gland biopsy; SGUS, salivary-gland ultrasonography. Categorical data were compared between responders and non-responders using the chi-square or Fisher&#x02019;s test as appropriate, and continuous data were compared using the Mann-Whitney test.</p></fn></table-wrap-foot></table-wrap><fig id="pone.0162787.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0162787.g001</object-id><label>Fig 1</label><caption><title>Flowchart of the patients from the TEARS study included in the present analyses.</title><p>SG, salivary gland. SSRI, Sj&#x000f6;gren&#x02019;s Syndrome Responder Index. SG biopsy and ultrasonography were performed at baseline at the discretion of the evaluating physician, as anticipated in the TEARS trial protocol.</p></caption><graphic xlink:href="pone.0162787.g001"/></fig></sec><sec id="sec008"><title>Salivary-gland ultrasonography [SGUS]</title><p>All 28 patients included at the Brest Teaching Hospital underwent baseline standardised SGUS by a single investigator [SJJ], who was, as all other investigators involved in the study, blinded to treatment allocation. All procedures were performed using the same ultrasound equipment: iU22 scanner (Philips Medical Systems, Andover, MA, USA), linear probe from 5 to 15 mHz. Both parotid and submandibular glands were evaluated. The echostructure of each gland was graded on a scale of 0 to 4 based on the presence or absence of hypoechoic areas, as previously described [<xref rid="pone.0162787.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0162787.ref010" ref-type="bibr">10</xref>]. Grade 0 indicated a normal homogeneous gland; grade 1, small hypoechoic areas without echogenic bands; grade 2, multiple hypoechoic areas measuring &#x0003c;2 mm, with hyperechoic bands; grade 3, multiple hypoechoic areas measuring 2&#x02013;6 mm, with hyperechoic bands; and grade 4, multiple hypoechoic areas measuring &#x0003e;6 mm or multiple calcifications with hyperechoic bands. In each patient, both the highest SGUS score of the four glands [range, 0&#x02013;4] and the four scores [range, 0&#x02013;16] were considered for the analysis.</p></sec><sec id="sec009"><title>Minor salivary gland biopsy [MSGB]</title><p>MSGB was performed routinely at 4 of the 14 participating centres [Brest, Lille, Nantes, and Rouen] at baseline. The biopsy specimens in paraffin blocks and the corresponding slides were sent to the coordinating centre in Brest and read by a single specifically trained pathologist [SC], as previously described [<xref rid="pone.0162787.ref024" ref-type="bibr">24</xref>]. The focus score was computed as the number of aggregates containing &#x0003e;50 lymphocytes per 4 mm&#x000b2; of normal-appearing salivary-gland tissue [<xref rid="pone.0162787.ref025" ref-type="bibr">25</xref>].</p></sec><sec id="sec010"><title>Sj&#x000f6;gren&#x02019;s Syndrome Response Index-30 [SSRI-30]</title><p>The SSRI-30 [<xref rid="pone.0162787.ref007" ref-type="bibr">7</xref>] is defined as at least 30% improvements between baseline and 6 months in at least two of five criteria: fatigue VAS, oral dryness VAS, ocular dryness VAS, UWSF, and erythrocyte sedimentation rate [ESR]. Among the 17 rituximab-treated patients included in the present study, 7 achieved the SSRI-30 at W24, 7 did not, and 3 had missing data precluding evaluation of the SSRI-30. Responders and non-responders to rituximab were comparable for demographic data and general characteristics of pSS [<xref ref-type="table" rid="pone.0162787.t001">Table 1</xref>]. Among the 18 patients from the placebo group, only 2 were considered responders at W24, 12 were non-responders, and 4 had missing data precluding evaluation of the SSRI-30.</p></sec><sec id="sec011"><title>Statistical analysis</title><p>Data were described as median [interquartile range] for continuous variables and number [percentage] for categorical variables. We computed Spearman&#x02019;s coefficients to assess potential correlations linking the three methods used to assess the baseline severity of salivary-gland involvement [SGUS, focus score, and UWSF]. We then evaluated whether baseline severity of salivary-gland involvement predicted the response to rituximab after 6 months. We compared patient groups using the Mann-Whitney, chi-square, or Fisher&#x02019;s test, as appropriate. All analyses were performed using GraphPad Prism software or SPSS v20. Values of <italic>p</italic>&#x0003c;0.05 were considered significant.</p></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><p>Of the 35 patients, 31 underwent centralised focus-score determination and 28 underwent SGUS; both were performed in 24 patients. UWSF was determined in all patients.</p><p>The global SGUS grade correlated positively to the focus score [r = 0.61, <italic>p</italic>&#x0003c;0.01, <xref ref-type="fig" rid="pone.0162787.g002">Fig 2A</xref>] and negatively to the UWSF [r = -0.68, <italic>p</italic>&#x0003c;0.001, <xref ref-type="fig" rid="pone.0162787.g002">Fig 2B</xref>]. We found no significant correlation between the focus score and UWSF [<xref ref-type="fig" rid="pone.0162787.g002">Fig 2C</xref>].</p><fig id="pone.0162787.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0162787.g002</object-id><label>Fig 2</label><caption><title>Salivary-gland ultrasonography grade correlates with salivary flow and histology.</title><p>SGUS, salivary gland ultrasonography; UWSF, unstimulated whole salivary flow. The total SGUS grade obtained by summing the grades of the two parotid and two submandibular glands can range from 0 to 16.</p></caption><graphic xlink:href="pone.0162787.g002"/></fig><p>In the rituximab group, we observed a trend towards a lower baseline UWSF in non-responders compared to responders [p = NS, <xref ref-type="table" rid="pone.0162787.t001">Table 1</xref>]. However, we were unable to identify a cut-off that reliably separated responders and non-responders [<xref ref-type="fig" rid="pone.0162787.g003">Fig 3A</xref>].</p><fig id="pone.0162787.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0162787.g003</object-id><label>Fig 3</label><caption><title>High salivary-gland ultrasonography grade and high focus score predict the response to rituximab.</title><p>SGUS, salivary gland ultrasonography; UWSF, unstimulated whole salivary flow. The response was assessed using the SSRI-30 (Sj&#x000f6;gren&#x02019;s Syndrome Response Index 30), defined as an at least 30% improvement from baseline to week 24 in at least two of the following five criteria: fatigue visual analogue scale [VAS], oral dryness VAS, ocular dryness VAS, unstimulated whole salivary flow, and erythrocyte sedimentation rate.</p></caption><graphic xlink:href="pone.0162787.g003"/></fig><p>The median total SGUS grade at W24 was 9 [<xref rid="pone.0162787.ref006" ref-type="bibr">6</xref>&#x02013;<xref rid="pone.0162787.ref011" ref-type="bibr">11</xref>] in responders to rituximab versus 16 [<xref rid="pone.0162787.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0162787.ref016" ref-type="bibr">16</xref>] in non-responders [<italic>p</italic> = 0.04, <xref ref-type="fig" rid="pone.0162787.g003">Fig 3B</xref>]. None of the 4 patients with the highest SGUS grade in at least one of the four glands achieved the SSRI-30 by W24. Of the 8 patients whose highest single-gland grade was &#x02264;3, 7 achieved the SSRI-30 [<xref ref-type="fig" rid="pone.0162787.g003">Fig 3C</xref>].</p><p>To better explore how baseline SGUS was associated with improvement after rituximab, we compared median baseline total SGUS grades between patients who experienced or not at least 30% improvement of each individual components of the SSRI (fatigue, oral and ocular dryness VAS, ESR and UWSF) at W24. Median baseline total SGUS grade was lower in patients who experienced a &#x02265;30% improvement from baseline for oral dryness VAS (6 [1.5&#x02013;8.5] vs 12 [8.5&#x02013;16], p = 0.04), ocular dryness VAS (2 [<xref rid="pone.0162787.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0162787.ref006" ref-type="bibr">6</xref>] vs 11 [<xref rid="pone.0162787.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0162787.ref016" ref-type="bibr">16</xref>], p = 0.02), and UWSF albeit not significantly (8 [<xref rid="pone.0162787.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0162787.ref010" ref-type="bibr">10</xref>] vs 12 [<xref rid="pone.0162787.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0162787.ref016" ref-type="bibr">16</xref>], p = 0.18), but not for fatigue VAS (9 [<xref rid="pone.0162787.ref004" ref-type="bibr">4</xref>&#x02013;<xref rid="pone.0162787.ref011" ref-type="bibr">11</xref>] vs 9.5 [<xref rid="pone.0162787.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0162787.ref016" ref-type="bibr">16</xref>], p = 0.83) nor for ESR (11.5 [<xref rid="pone.0162787.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0162787.ref014" ref-type="bibr">14</xref>] vs 8.5 [<xref rid="pone.0162787.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0162787.ref016" ref-type="bibr">16</xref>], p = 0.47).</p><p>In the rituximab-treated group, the proportion of patients who achieved the SSRI-30 by W24 was 1/7 [14%] in the group with a focus score &#x0003e;2 versus 6/7 [86%] in the group with a focus score &#x0003c;2. The median baseline focus score was 0.3 [0.0&#x02013;1.3] in the responders versus 4.0 [2.7&#x02013;5.3] in the non-responders [<italic>p</italic> = 0.02, <xref ref-type="fig" rid="pone.0162787.g003">Fig 3D</xref>].</p></sec><sec sec-type="conclusions" id="sec013"><title>Discussion</title><p>In our patients with pSS, salivary-gland structure as assessed using SGUS correlated closely with both salivary gland function and histology. Furthermore, the severity of salivary-gland involvement as assessed by SGUS or histology was associated with the response to rituximab after 6 months, whereas UWSF was not.</p><p>UWSF has some limitations such as imprecision and variability [<xref rid="pone.0162787.ref026" ref-type="bibr">26</xref>]. However, it is the most widely used test to assess salivary gland functional involvement in pSS and is included in most classification criteria [<xref rid="pone.0162787.ref023" ref-type="bibr">23</xref>]. Several studies have shown that its value progressively decreases with time in patients with recent disease [<xref rid="pone.0162787.ref027" ref-type="bibr">27</xref>], and rituximab was able to slow this decrease over 6 months in the TEARS study [<xref rid="pone.0162787.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0162787.ref007" ref-type="bibr">7</xref>]. Nonetheless, we did not find here that baseline salivary gland functional impairment was clearly associated with response to rituximab.</p><p>That rituximab was not effective in patients with the highest SGUS grade or a high focus score at baseline might be ascribable to irreversible salivary-gland damage due to long-standing disease. However, neither age nor disease duration differed significantly between responders and non-responders. Moreover, the patients with high focus scores did not exhibit histological features of irreversible salivary-gland destruction such as fibrosis or adiposis [<xref rid="pone.0162787.ref024" ref-type="bibr">24</xref>]. We have shown here that the focus score and the SGUS score are highly correlated. Thus, the hypoechoic areas detected using SGUS may indicate tissue inflammation rather than tissue damage. Further studies using objective tools to assess tissue fibrosis within salivary glands, such as ultrasonographic elastometry [<xref rid="pone.0162787.ref028" ref-type="bibr">28</xref>&#x02013;<xref rid="pone.0162787.ref030" ref-type="bibr">30</xref>], would be useful to better understand the significance of these findings, as well as direct comparison of parotid gland biopsy and ultrasonography [<xref rid="pone.0162787.ref031" ref-type="bibr">31</xref>]. Until such studies, comparing directly SGUS findings and histologic analysis of the same glands, are performed, it remains speculative to affirm whether the SGUS hypoechoic areas correspond more to inflammation or to fibrosis/scaring of salivary gland tissue.</p><p>Recent publications described the effects of rituximab on salivary-gland infiltrating lymphocyte subsets in pSS patients and their relationship with clinical efficacy. In salivary-gland biopsy samples from the TEARS study and from a previous open-labelled pilot study [<xref rid="pone.0162787.ref032" ref-type="bibr">32</xref>], we assessed the evolution of the proportion of B cells among the lymphocytic infiltrate using an original digital procedure to analyse objectively immunohistochemistry slides [<xref rid="pone.0162787.ref033" ref-type="bibr">33</xref>]. Rituximab infusions induced a drastic decrease of salivary gland B-cell proportion 3 months later, but B cells reappeared within salivary-gland tissue as soon as they were detectable in the peripheral blood [<xref rid="pone.0162787.ref034" ref-type="bibr">34</xref>]. We also observed that patients with the highest B-cell proportion in minor salivary glands at baseline were less likely to be improved by rituximab as defined by the SSRI at 6 months. These observations further suggest that salivary gland hypoechoic lesions, as measured by the SGUS score in the present study, are associated with a higher degree of minor salivary gland inflammation that could impact rituximab efficacy. Interestingly, another study reported that patients with the highest absolute numbers of B cells within the parotid glands were conversely more likely to respond to rituximab as defined by ESSDAI improvement [<xref rid="pone.0162787.ref035" ref-type="bibr">35</xref>], highlighting again the differences between minor and major salivary gland pathology and the need to define consensual response criteria in pSS [<xref rid="pone.0162787.ref036" ref-type="bibr">36</xref>,<xref rid="pone.0162787.ref037" ref-type="bibr">37</xref>].</p><p>The 6-month follow-up and the single rituximab course in the TEARS trial may have been too short to assess treatment responses, given the slow pace of progression of pSS. Further rituximab therapy might be effective, however, even in patients with the most severe SGUS morphologic lesions at baseline. Indeed, we previously observed that rituximab induced an improvement of SGUS score in half of the patients of the TEARS study [<xref rid="pone.0162787.ref019" ref-type="bibr">19</xref>]. Specifically, if none of the four patients with baseline severe parotid echostructure abnormality (maximal grade = 4) were considered responders at W24 according to the SSRI, three of them experienced a decrease of maximal SGUS score at 6 months (maximal grade = 3) [<xref rid="pone.0162787.ref019" ref-type="bibr">19</xref>]. We could thus hypothesize that a second rituximab course given at this time would then be able to improve disease activity. This possibility is being assessed in the TRACTISS study in the United-Kingdom (ISRCTN65360827), a large placebo-controlled trial of two rituximab courses in pSS with an assessment of the clinical response after 12 months [<xref rid="pone.0162787.ref038" ref-type="bibr">38</xref>]. Long-term follow-up will be needed in future studies, both in clinical trials and in every-day life cohorts, to define the efficacy of different therapeutic strategies in pSS and to better determine the evolution of SGUS lesions spontaneously and after therapy. This study, despite a small number of patients included, is the first to show that a single rituximab course does not induce a significant clinical response in half of pSS patients, who display the most severe salivary gland involvement. Therefore, SGUS and salivary gland histology could be considered as simple, non-invasive and accessible biomarkers to predict the response to therapy in this difficult-to-treat disease, and help designing inclusion criteria in future trials. New studies, including higher number of patients, different treatment strategies and longer follow-up, are needed to confirm these preliminary observations and validate the clinical utility of SGUS and salivary gland histology as biomarkers.</p></sec><sec sec-type="supplementary-material" id="sec014"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0162787.s001"><label>S1 Checklist</label><caption><title>CONSORT Checklist.</title><p>(DOC)</p></caption><media xlink:href="pone.0162787.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0162787.s002"><label>S1 Dataset</label><caption><title>Minimal Dataset.</title><p>(XLSX)</p></caption><media xlink:href="pone.0162787.s002.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0162787.s003"><label>S1 Protocol</label><caption><title>English Protocol.</title><p>(DOCX)</p></caption><media xlink:href="pone.0162787.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0162787.s004"><label>S2 Protocol</label><caption><title>French Protocol.</title><p>(PDF)</p></caption><media xlink:href="pone.0162787.s004.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0162787.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Chiche</surname><given-names>L</given-names></name>. <article-title>Is primary Sj&#x000f6;gren&#x02019;s syndrome an orphan disease? A critical appraisal of prevalence studies in Europe</article-title>. <source>Ann Rheum Dis</source>. <year>2014</year>; annrheumdis-2014-206860. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/annrheumdis-2014-206860">10.1136/annrheumdis-2014-206860</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Sankar</surname><given-names>V</given-names></name>, <name><surname>Brennan</surname><given-names>MT</given-names></name>, <name><surname>Kok</surname><given-names>MR</given-names></name>, <name><surname>Leakan</surname><given-names>RA</given-names></name>, <name><surname>Smith</surname><given-names>JA</given-names></name>, <name><surname>Manny</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Etanercept in Sj&#x000f6;gren&#x02019;s syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial</article-title>. <source>Arthritis Rheum</source>. <year>2004</year>;<volume>50</volume>: <fpage>2240</fpage>&#x02013;<lpage>2245</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.20299">10.1002/art.20299</ext-link></comment>
<pub-id pub-id-type="pmid">15248223</pub-id></mixed-citation></ref><ref id="pone.0162787.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Mariette</surname><given-names>X</given-names></name>, <name><surname>Ravaud</surname><given-names>P</given-names></name>, <name><surname>Steinfeld</surname><given-names>S</given-names></name>, <name><surname>Baron</surname><given-names>G</given-names></name>, <name><surname>Goetz</surname><given-names>J</given-names></name>, <name><surname>Hachulla</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Inefficacy of infliximab in primary Sj&#x000f6;gren&#x02019;s syndrome: Results of the randomized, controlled trial of remicade in primary Sj&#x000f6;gren&#x02019;s syndrome (TRIPSS)</article-title>. <source>Arthritis Rheum</source>. <year>2004</year>;<volume>50</volume>: <fpage>1270</fpage>&#x02013;<lpage>1276</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.20146">10.1002/art.20146</ext-link></comment>
<pub-id pub-id-type="pmid">15077311</pub-id></mixed-citation></ref><ref id="pone.0162787.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Gottenberg</surname><given-names>J-E</given-names></name>, <name><surname>Ravaud</surname><given-names>P</given-names></name>, <name><surname>Pu&#x000e9;chal</surname><given-names>X</given-names></name>, <name><surname>Le Guern</surname><given-names>V</given-names></name>, <name><surname>Sibilia</surname><given-names>J</given-names></name>, <name><surname>Goeb</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Effects of hydroxychloroquine on symptomatic improvement in primary Sj&#x000f6;gren syndrome: the JOQUER randomized clinical trial</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>312</volume>: <fpage>249</fpage>&#x02013;<lpage>258</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.2014.7682">10.1001/jama.2014.7682</ext-link></comment>
<pub-id pub-id-type="pmid">25027140</pub-id></mixed-citation></ref><ref id="pone.0162787.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name>, <name><surname>Tob&#x000f3;n</surname><given-names>GJ</given-names></name>, <name><surname>Pers</surname><given-names>J-O</given-names></name>, <name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <name><surname>Saraux</surname><given-names>A</given-names></name>. <article-title>B cells in Sj&#x000f6;gren&#x02019;s syndrome: From pathophysiology to diagnosis and treatment</article-title>. <source>J Autoimmun</source>. <year>2012</year>;<volume>39</volume>: <fpage>161</fpage>&#x02013;<lpage>167</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jaut.2012.05.014">10.1016/j.jaut.2012.05.014</ext-link></comment>
<pub-id pub-id-type="pmid">22749831</pub-id></mixed-citation></ref><ref id="pone.0162787.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name>, <name><surname>Mariette</surname><given-names>X</given-names></name>, <name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <name><surname>Berthelot</surname><given-names>J-M</given-names></name>, <name><surname>Perdriger</surname><given-names>A</given-names></name>, <name><surname>Pu&#x000e9;chal</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Treatment of Primary Sj&#x000f6;gren Syndrome With RituximabA Randomized Trial</article-title>. <source>Ann Intern Med</source>. <year>2014</year>;<volume>160</volume>: <fpage>233</fpage>&#x02013;<lpage>242</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.7326/M13-1085">10.7326/M13-1085</ext-link></comment>
<pub-id pub-id-type="pmid">24727841</pub-id></mixed-citation></ref><ref id="pone.0162787.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name>, <name><surname>Mariette</surname><given-names>X</given-names></name>, <name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <name><surname>Berthelot</surname><given-names>J-M</given-names></name>, <name><surname>Perdriger</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Development of the Sj&#x000f6;gren&#x02019;s Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy</article-title>. <source>Rheumatology</source>. <year>2015</year>; kev114. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/rheumatology/kev114">10.1093/rheumatology/kev114</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Pijpe</surname><given-names>J</given-names></name>, <name><surname>van Imhoff</surname><given-names>GW</given-names></name>, <name><surname>Spijkervet</surname><given-names>FKL</given-names></name>, <name><surname>Roodenburg</surname><given-names>JLN</given-names></name>, <name><surname>Wolbink</surname><given-names>GJ</given-names></name>, <name><surname>Mansour</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Rituximab treatment in patients with primary Sj&#x000f6;gren&#x02019;s syndrome: An open-label phase II study</article-title>. <source>Arthritis Rheum</source>. <year>2005</year>;<volume>52</volume>: <fpage>2740</fpage>&#x02013;<lpage>2750</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.21260">10.1002/art.21260</ext-link></comment>
<pub-id pub-id-type="pmid">16142737</pub-id></mixed-citation></ref><ref id="pone.0162787.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <name><surname>Pers</surname><given-names>J-O</given-names></name>, <name><surname>Marhadour</surname><given-names>T</given-names></name>, <name><surname>Cochener</surname><given-names>B</given-names></name>, <name><surname>Boisram&#x000e9;-Gastrin</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Contribution of salivary gland ultrasonography to the diagnosis of Sj&#x000f6;gren&#x02019;s syndrome: Toward new diagnostic criteria?</article-title>
<source>Arthritis Rheum</source>. <year>2013</year>;<volume>65</volume>: <fpage>216</fpage>&#x02013;<lpage>225</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.37698">10.1002/art.37698</ext-link></comment>
<pub-id pub-id-type="pmid">23108632</pub-id></mixed-citation></ref><ref id="pone.0162787.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <name><surname>Marhadour</surname><given-names>T</given-names></name>, <name><surname>Pers</surname><given-names>J-O</given-names></name>, <name><surname>Boisram&#x000e9;-Gastrin</surname><given-names>S</given-names></name>, <name><surname>Renaudineau</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Salivary gland ultrasonography improves the diagnostic performance of the 2012 American College of Rheumatology classification criteria for Sj&#x000f6;gren&#x02019;s syndrome</article-title>. <source>Rheumatology</source>. <year>2014</year>; keu037. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/rheumatology/keu037">10.1093/rheumatology/keu037</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Hammenfors</surname><given-names>DS</given-names></name>, <name><surname>Brun</surname><given-names>JG</given-names></name>, <name><surname>Jonsson</surname><given-names>R</given-names></name>, <name><surname>Jonsson</surname><given-names>MV</given-names></name>. <article-title>Diagnostic utility of major salivary gland ultrasonography in primary Sj&#x000f6;gren&#x02019;s syndrome</article-title>. <source>Clin Exp Rheumatol</source>. <year>2015</year>;<volume>33</volume>: <fpage>56</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="pmid">25535773</pub-id></mixed-citation></ref><ref id="pone.0162787.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Theander</surname><given-names>E</given-names></name>, <name><surname>Mandl</surname><given-names>T</given-names></name>. <article-title>Primary Sj&#x000f6;gren&#x02019;s syndrome: diagnostic and prognostic value of salivary gland ultrasonography using a simplified scoring system</article-title>. <source>Arthritis Care Res</source>. <year>2014</year>;<volume>66</volume>: <fpage>1102</fpage>&#x02013;<lpage>1107</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/acr.22264">10.1002/acr.22264</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Takagi</surname><given-names>Y</given-names></name>, <name><surname>Sumi</surname><given-names>M</given-names></name>, <name><surname>Nakamura</surname><given-names>H</given-names></name>, <name><surname>Iwamoto</surname><given-names>N</given-names></name>, <name><surname>Horai</surname><given-names>Y</given-names></name>, <name><surname>Kawakami</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Ultrasonography as an additional item in the American College of Rheumatology classification of Sj&#x000f6;gren&#x02019;s syndrome</article-title>. <source>Rheumatol Oxf Engl</source>. <year>2014</year>;<volume>53</volume>: <fpage>1977</fpage>&#x02013;<lpage>1983</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/rheumatology/keu238">10.1093/rheumatology/keu238</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Baldini</surname><given-names>C</given-names></name>, <name><surname>Luciano</surname><given-names>N</given-names></name>, <name><surname>Tarantini</surname><given-names>G</given-names></name>, <name><surname>Pascale</surname><given-names>R</given-names></name>, <name><surname>Sernissi</surname><given-names>F</given-names></name>, <name><surname>Mosca</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Salivary gland ultrasonography: a highly specific tool for the early diagnosis of primary Sj&#x000f6;gren&#x02019;s syndrome</article-title>. <source>Arthritis Res Ther</source>. <year>2015</year>;<volume>17</volume>: <fpage>146</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13075-015-0657-7">10.1186/s13075-015-0657-7</ext-link></comment>
<pub-id pub-id-type="pmid">26022533</pub-id></mixed-citation></ref><ref id="pone.0162787.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Delli</surname><given-names>K</given-names></name>, <name><surname>Dijkstra</surname><given-names>PU</given-names></name>, <name><surname>Stel</surname><given-names>AJ</given-names></name>, <name><surname>Bootsma</surname><given-names>H</given-names></name>, <name><surname>Vissink</surname><given-names>A</given-names></name>, <name><surname>Spijkervet</surname><given-names>FKL</given-names></name>. <article-title>Diagnostic properties of ultrasound of major salivary glands in Sj&#x000f6;gren&#x02019;s syndrome: a meta-analysis</article-title>. <source>Oral Dis</source>. <year>2015</year>;<volume>21</volume>: <fpage>792</fpage>&#x02013;<lpage>800</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/odi.12349">10.1111/odi.12349</ext-link></comment>
<pub-id pub-id-type="pmid">25988616</pub-id></mixed-citation></ref><ref id="pone.0162787.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name>, <name><surname>Saraux</surname><given-names>A</given-names></name>, <name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>. [<article-title>Clinical usefulness of salivary gland ultrasonography in Sj&#x000f6;gren&#x02019;s syndrome: Where are we now?</article-title>]. <source>Rev M&#x000e9;decine Interne Fond&#x000e9;e Par Soci&#x000e9;t&#x000e9; Natl Francaise M&#x000e9;decine Interne</source>. <year>2016</year>;<volume>37</volume>: <fpage>186</fpage>&#x02013;<lpage>194</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.revmed.2015.10.341">10.1016/j.revmed.2015.10.341</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <name><surname>Milic</surname><given-names>V</given-names></name>, <name><surname>Jonsson</surname><given-names>MV</given-names></name>, <name><surname>Plagou</surname><given-names>A</given-names></name>, <name><surname>Theander</surname><given-names>E</given-names></name>, <name><surname>Luciano</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Is salivary gland ultrasonography a useful tool in Sj&#x000f6;gren&#x02019;s syndrome? A systematic review</article-title>. <source>Rheumatol Oxf Engl</source>. <year>2015</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/rheumatology/kev385">10.1093/rheumatology/kev385</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <name><surname>Saraux</surname><given-names>A</given-names></name>, <name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name>. <article-title>Salivary gland ultrasound to diagnose Sj&#x000f6;gren&#x02019;s syndrome: a claim to standardize the procedure</article-title>. <source>Rheumatol Oxf Engl</source>. <year>2015</year>;<volume>54</volume>: <fpage>199</fpage>&#x02013;<lpage>200</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/rheumatology/keu397">10.1093/rheumatology/keu397</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name>, <name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Marhadour</surname><given-names>T</given-names></name>, <name><surname>Bressollette</surname><given-names>L</given-names></name>, <name><surname>Gestin</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Ultrasonographic salivary gland response to rituximab in primary Sj&#x000f6;gren&#x02019;s syndrome</article-title>. <source>Arthritis Rheumatol Hoboken NJ</source>. <year>2015</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.39088">10.1002/art.39088</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Risselada</surname><given-names>AP</given-names></name>, <name><surname>Kruize</surname><given-names>AA</given-names></name>, <name><surname>Goldschmeding</surname><given-names>R</given-names></name>, <name><surname>Lafeber</surname><given-names>FPJG</given-names></name>, <name><surname>Bijlsma</surname><given-names>JWJ</given-names></name>, <name><surname>van Roon</surname><given-names>JAG</given-names></name>. <article-title>The prognostic value of routinely performed minor salivary gland assessments in primary Sj&#x000f6;gren&#x02019;s syndrome</article-title>. <source>Ann Rheum Dis</source>. <year>2014</year>;<volume>73</volume>: <fpage>1537</fpage>&#x02013;<lpage>1540</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/annrheumdis-2013-204634">10.1136/annrheumdis-2013-204634</ext-link></comment>
<pub-id pub-id-type="pmid">24525912</pub-id></mixed-citation></ref><ref id="pone.0162787.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Carubbi</surname><given-names>F</given-names></name>, <name><surname>Alunno</surname><given-names>A</given-names></name>, <name><surname>Cipriani</surname><given-names>P</given-names></name>, <name><surname>Di Benedetto</surname><given-names>P</given-names></name>, <name><surname>Ruscitti</surname><given-names>P</given-names></name>, <name><surname>Berardicurti</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Is minor salivary gland biopsy more than a diagnostic tool in primary Sj&#x000f6;gren&#x005f3;s syndrome? Association between clinical, histopathological, and molecular features: a retrospective study</article-title>. <source>Semin Arthritis Rheum</source>. <year>2014</year>;<volume>44</volume>: <fpage>314</fpage>&#x02013;<lpage>324</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.semarthrit.2014.05.015">10.1016/j.semarthrit.2014.05.015</ext-link></comment>
<pub-id pub-id-type="pmid">24935529</pub-id></mixed-citation></ref><ref id="pone.0162787.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Fisher</surname><given-names>BA</given-names></name>, <name><surname>Brown</surname><given-names>RM</given-names></name>, <name><surname>Bowman</surname><given-names>SJ</given-names></name>, <name><surname>Barone</surname><given-names>F</given-names></name>. <article-title>A review of salivary gland histopathology in primary Sj&#x000f6;gren&#x02019;s syndrome with a focus on its potential as a clinical trials biomarker</article-title>. <source>Ann Rheum Dis</source>. <year>2015</year>; annrheumdis-2015-207499. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/annrheumdis-2015-207499">10.1136/annrheumdis-2015-207499</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Vitali</surname><given-names>C</given-names></name>, <name><surname>Bombardieri</surname><given-names>S</given-names></name>, <name><surname>Jonsson</surname><given-names>R</given-names></name>, <name><surname>Moutsopoulos</surname><given-names>HM</given-names></name>, <name><surname>Alexander</surname><given-names>EL</given-names></name>, <name><surname>Carsons</surname><given-names>SE</given-names></name>, <etal>et al</etal>
<article-title>Classification criteria for Sj&#x000f6;gren&#x02019;s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group</article-title>. <source>Ann Rheum Dis</source>. <year>2002</year>;<volume>61</volume>: <fpage>554</fpage>&#x02013;<lpage>558</lpage>. <pub-id pub-id-type="pmid">12006334</pub-id></mixed-citation></ref><ref id="pone.0162787.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Costa</surname><given-names>S</given-names></name>, <name><surname>Quintin-Rou&#x000e9;</surname><given-names>I</given-names></name>, <name><surname>Lesourd</surname><given-names>A</given-names></name>, <name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <name><surname>Berthelot</surname><given-names>J-M</given-names></name>, <name><surname>Hachulla</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Reliability of histopathological salivary gland biopsy assessment in Sj&#x000f6;gren&#x02019;s syndrome: a multicentre cohort study</article-title>. <source>Rheumatol Oxf Engl</source>. <year>2014</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/rheumatology/keu453">10.1093/rheumatology/keu453</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Daniels</surname><given-names>TE</given-names></name>. <article-title>Labial salivary gland biopsy in Sj&#x000f6;gren&#x02019;s syndrome. Assessment as a diagnostic criterion in 362 suspected cases</article-title>. <source>Arthritis Rheum</source>. <year>1984</year>;<volume>27</volume>: <fpage>147</fpage>&#x02013;<lpage>156</lpage>. <pub-id pub-id-type="pmid">6696772</pub-id></mixed-citation></ref><ref id="pone.0162787.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Jorkjend</surname><given-names>L</given-names></name>, <name><surname>Johansson</surname><given-names>A</given-names></name>, <name><surname>Johansson</surname><given-names>A-K</given-names></name>, <name><surname>Bergenholtz</surname><given-names>A</given-names></name>. <article-title>Resting and stimulated whole salivary flow rates in Sj&#x000f6;gren&#x02019;s syndrome patients over time: a diagnostic aid for subsidized dental care?</article-title>
<source>Acta Odontol Scand</source>. <year>2004</year>;<volume>62</volume>: <fpage>264</fpage>&#x02013;<lpage>268</lpage>. <pub-id pub-id-type="pmid">15841813</pub-id></mixed-citation></ref><ref id="pone.0162787.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Pijpe</surname><given-names>J</given-names></name>, <name><surname>Kalk</surname><given-names>WWI</given-names></name>, <name><surname>Bootsma</surname><given-names>H</given-names></name>, <name><surname>Spijkervet</surname><given-names>FKL</given-names></name>, <name><surname>Kallenberg</surname><given-names>CGM</given-names></name>, <name><surname>Vissink</surname><given-names>A</given-names></name>. <article-title>Progression of salivary gland dysfunction in patients with Sj&#x000f6;gren&#x02019;s syndrome</article-title>. <source>Ann Rheum Dis</source>. <year>2007</year>;<volume>66</volume>: <fpage>107</fpage>&#x02013;<lpage>112</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/ard.2006.052647">10.1136/ard.2006.052647</ext-link></comment>
<pub-id pub-id-type="pmid">16728458</pub-id></mixed-citation></ref><ref id="pone.0162787.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Samier-Gu&#x000e9;rin</surname><given-names>A</given-names></name>, <name><surname>Saraux</surname><given-names>A</given-names></name>, <name><surname>Gestin</surname><given-names>S</given-names></name>, <name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Marhadour</surname><given-names>T</given-names></name>, <name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Can ARFI elastometry of the salivary glands contribute to the diagnosis of Sj&#x000f6;gren&#x02019;s syndrome?</article-title>
<source>Jt Bone Spine Rev Rhum</source>. <year>2015</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jbspin.2015.11.002">10.1016/j.jbspin.2015.11.002</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Knopf</surname><given-names>A</given-names></name>, <name><surname>Hofauer</surname><given-names>B</given-names></name>, <name><surname>Th&#x000fc;rmel</surname><given-names>K</given-names></name>, <name><surname>Meier</surname><given-names>R</given-names></name>, <name><surname>Stock</surname><given-names>K</given-names></name>, <name><surname>Bas</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Diagnostic utility of Acoustic Radiation Force Impulse (ARFI) imaging in primary Sjoegren`s syndrome</article-title>. <source>Eur Radiol</source>. <year>2015</year>;<volume>25</volume>: <fpage>3027</fpage>&#x02013;<lpage>3034</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00330-015-3705-4">10.1007/s00330-015-3705-4</ext-link></comment>
<pub-id pub-id-type="pmid">25861884</pub-id></mixed-citation></ref><ref id="pone.0162787.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>S</given-names></name>, <name><surname>Zhu</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>He</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>. <article-title>Assessment of the Stiffness of Major Salivary Glands in Primary Sj&#x000f6;gren&#x02019;s Syndrome through Quantitative Acoustic Radiation Force Impulse Imaging</article-title>. <source>Ultrasound Med Biol</source>. <year>2016</year>;<volume>42</volume>: <fpage>645</fpage>&#x02013;<lpage>653</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ultrasmedbio.2015.11.009">10.1016/j.ultrasmedbio.2015.11.009</ext-link></comment>
<pub-id pub-id-type="pmid">26715188</pub-id></mixed-citation></ref><ref id="pone.0162787.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Pijpe</surname><given-names>J</given-names></name>, <name><surname>Kalk</surname><given-names>WWI</given-names></name>, <name><surname>Wal van der</surname><given-names>JE</given-names></name>, <name><surname>Vissink</surname><given-names>A</given-names></name>, <name><surname>Kluin</surname><given-names>PM</given-names></name>, <name><surname>Roodenburg</surname><given-names>JLN</given-names></name>, <etal>et al</etal>
<article-title>Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sj&#x000f6;gren&#x02019;s syndrome</article-title>. <source>Rheumatology</source>. <year>2007</year>;<volume>46</volume>: <fpage>335</fpage>&#x02013;<lpage>341</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/rheumatology/kel266">10.1093/rheumatology/kel266</ext-link></comment>
<pub-id pub-id-type="pmid">16891656</pub-id></mixed-citation></ref><ref id="pone.0162787.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name>, <name><surname>Pennec</surname><given-names>Y</given-names></name>, <name><surname>Morvan</surname><given-names>J</given-names></name>, <name><surname>Pers</surname><given-names>J-O</given-names></name>, <name><surname>Daridon</surname><given-names>C</given-names></name>, <name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Improvement of Sj&#x000f6;gren&#x02019;s syndrome after two infusions of rituximab (anti-CD20)</article-title>. <source>Arthritis Care Res</source>. <year>2007</year>;<volume>57</volume>: <fpage>310</fpage>&#x02013;<lpage>317</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.22536">10.1002/art.22536</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Costa</surname><given-names>S</given-names></name>, <name><surname>Schutz</surname><given-names>S</given-names></name>, <name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Uguen</surname><given-names>A</given-names></name>, <name><surname>Quintin-Rou&#x000e9;</surname><given-names>I</given-names></name>, <name><surname>Lesourd</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>B-cell and T-cell quantification in minor salivary glands in primary Sj&#x000f6;gren&#x02019;s syndrome: development and validation of a pixel-based digital procedure</article-title>. <source>Arthritis Res Ther</source>. <year>2016</year>;<volume>18</volume>: <fpage>21</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13075-016-0924-2">10.1186/s13075-016-0924-2</ext-link></comment>
<pub-id pub-id-type="pmid">26785742</pub-id></mixed-citation></ref><ref id="pone.0162787.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Costa</surname><given-names>S</given-names></name>, <name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name>, <name><surname>Jousse-Joulin</surname><given-names>S</given-names></name>, <name><surname>Marcorelles</surname><given-names>P</given-names></name>, <name><surname>Berthelot</surname><given-names>J-M</given-names></name>, <etal>et al</etal>
<article-title>Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sj&#x000f6;gren&#x02019;s syndrome</article-title>. <source>J Autoimmun</source>. <year>2016</year>;<volume>67</volume>: <fpage>102</fpage>&#x02013;<lpage>110</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jaut.2015.11.002">10.1016/j.jaut.2015.11.002</ext-link></comment>
<pub-id pub-id-type="pmid">26688003</pub-id></mixed-citation></ref><ref id="pone.0162787.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Delli</surname><given-names>K</given-names></name>, <name><surname>Haacke</surname><given-names>EA</given-names></name>, <name><surname>Kroese</surname><given-names>FGM</given-names></name>, <name><surname>Pollard</surname><given-names>RP</given-names></name>, <name><surname>Ihrler</surname><given-names>S</given-names></name>, <name><surname>Vegt van der</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Towards personalised treatment in primary Sj&#x000f6;gren&#x02019;s syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment</article-title>. <source>Ann Rheum Dis</source>. <year>2016</year>; annrheumdis-2015-208304. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/annrheumdis-2015-208304">10.1136/annrheumdis-2015-208304</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Cornec</surname><given-names>D</given-names></name>, <name><surname>Costa</surname><given-names>S</given-names></name>, <name><surname>Devauchelle-Pensec</surname><given-names>V</given-names></name>, <name><surname>Chiche</surname><given-names>L</given-names></name>, <name><surname>Saraux</surname><given-names>A</given-names></name>, <name><surname>Pers</surname><given-names>J-O</given-names></name>. <article-title>Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sj&#x000f6;gren&#x02019;s syndrome?</article-title>
<source>Ann Rheum Dis</source>. <year>2016</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/annrheumdis-2016-209300">10.1136/annrheumdis-2016-209300</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Delli</surname><given-names>K</given-names></name>, <name><surname>Haacke</surname><given-names>EA</given-names></name>, <name><surname>Kroese</surname><given-names>FG</given-names></name>, <name><surname>Pollard</surname><given-names>RP</given-names></name>, <name><surname>Ihrler</surname><given-names>S</given-names></name>, <name><surname>van der Vegt</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>In primary Sj&#x000f6;gren&#x02019;s syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI</article-title>. <source>Ann Rheum Dis</source>. <year>2016</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/annrheumdis-2016-209317">10.1136/annrheumdis-2016-209317</ext-link></comment></mixed-citation></ref><ref id="pone.0162787.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>S</given-names></name>, <name><surname>Coy</surname><given-names>NN</given-names></name>, <name><surname>Pitzalis</surname><given-names>C</given-names></name>, <name><surname>Emery</surname><given-names>P</given-names></name>, <name><surname>Pavitt</surname><given-names>S</given-names></name>, <name><surname>Gray</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjogren&#x02019;s Syndrome</article-title>. <source>BMC Musculoskelet Disord</source>. <year>2014</year>;<volume>15</volume>: <fpage>21</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2474-15-21">10.1186/1471-2474-15-21</ext-link></comment>
<pub-id pub-id-type="pmid">24438039</pub-id></mixed-citation></ref></ref-list></back></article>